Recent advances in diagnostic tools have revolutionized the field of lymphoma treatment. Within this progress, liquid biopsy has emerged as a promising approach for detecting minimal residual disease (MRD). Unlike traditional biopsies that require tissue sampling, liquid biopsies analyze circulating tumor cells (CTCs) and unbound DNA in the blood.

Minimal residual disease (MRD) screening is crucial in lymphoma management as it predicts relapse risk and guides therapeutic decisions. Traditional MRD methods often involve invasive biopsies, leading to patient discomfort and potential complications. Liquid biopsy, a non-invasive technique analyzing circulating tumor cells (CTCs) and cell-free DN

Minimal residual disease (MRD) detection is crucial in lymphoma management as it predicts relapse risk and guides therapeutic decisions. Traditional MRD methods often involve invasive biopsies, leading to patient discomfort and potential complications. Liquid biopsy, a non-invasive technique analyzing circulating tumor cells (CTCs) and cell-free DN

Minimal residual disease (MRD) identification is crucial in lymphoma management as it predicts relapse risk and guides therapeutic decisions. Traditional MRD methods often involve invasive biopsies, leading to patient discomfort and potential complications. Liquid biopsy, a non-invasive technique analyzing circulating tumor cells (CTCs) and cell-fr

Minimal residual disease (MRD) identification is crucial in lymphoma management as it predicts relapse risk and guides therapeutic decisions. Traditional MRD methods often involve invasive biopsies, leading to patient discomfort and potential complications. Liquid biopsy, a non-invasive technique analyzing circulating tumor cells (CTCs) and cell-fr